These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21454244)

  • 1. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.
    Miller J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Endocr Pract; 2011; 17(4):574-83. PubMed ID: 21454244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies.
    Efros M; Carrara D; Neijber A
    Andrologia; 2016 Aug; 48(6):637-45. PubMed ID: 26598279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
    Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.
    Morgentaler A; McGettigan J; Xiang Q; Danoff TM; Gould EM
    Int J Impot Res; 2015; 27(2):41-5. PubMed ID: 25056809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy men.
    Olsson H; Sandström R; Neijber A; Carrara D; Grundemar L
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):358-64. PubMed ID: 27129008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW; Matthias D; Hoffman AR
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application.
    Yu Z; Gupta SK; Hwang SS; Cook DM; Duckett MJ; Atkinson LE
    J Clin Pharmacol; 1997 Dec; 37(12):1129-38. PubMed ID: 9506008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
    McMahon CG; Shusterman N; Cohen B
    J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
    Rogol AD; Tkachenko N; Bryson N
    Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Testim gel.
    McNicholas T; Ong T
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
    Dobs AS; Matsumoto AM; Wang C; Kipnes MS
    Curr Med Res Opin; 2004 May; 20(5):729-38. PubMed ID: 15140340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.